Navigation Links
Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II,trial of Cloretazine (VNP40101M) in Patients with Relapsed or,Refractory Small Cell Lung Cancer

bstantially reduced at the 100 mg/m2 dose, where 5 of 24 patients (21%) had grade 3 or 4 thrombocytopenia.

Small cell lung cancer metastasizes frequently to the bone marrow and the brain. Eighteen patients on the study presented with brain metastases. Of these patients, 3 achieved a partial systemic response and 3 demonstrated stable disease.

Dr. F. Anthony Greco, Director of the Sarah Cannon Research Institute in Nashville, Tennessee, commented, "Cloretazine(R) (VNP40101M) has impressive activity in small cell lung cancer in the second-line setting, including activity against brain metastases, and further evaluation is warranted."

Ann Cahill, Vion's Vice President, Clinical Development, said, "Our solid tumor clinical development plan for Cloretazine(R) (VNP40101M), which includes our Phase II trial in small cell lung cancer, and the recently completed trials in adult and pediatric brain tumors, is an important part of the overall clinical development program for this novel alkylating agent." Ms. Cahill added, "We are encouraged by this promising data in small cell lung cancer."

Additional data from a Phase I trial conducted by the Pediatric Brain Tumor Consortium of Cloretazine(R) (VNP40101M) as a single agent in pediatric brain tumors will be presented at the ASCO Annual Meeting in poster U1 in S Hall A2 at the McCormick Place Convention Center on Monday, June 4, 2007 from 1 to 5 p.m.

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. An additional trial of Cloretazine(R) (VNP40101M) as a single agent in small cell lung cancer is also underway
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:9/2/2015)... , Sept. 2, 2015  OncoSec Medical Incorporated ... intratumoral cancer immunotherapies, announced today that members of its ... events in September, including: , First ... Biology, Medicine and Food & Environmental Technologies; Portoroz, ... 17th Annual Global Investment Conference; New York, ...
(Date:9/2/2015)... 2015 China Nepstar Chain Drugstore Ltd. (NYSE: ... retail drugstore chain in China based on the number ... results for the second quarter ended June 30, 2015. ... 2015: , Revenue increased by 12.9% to RMB775.1 ... second quarter of 2014 , Same store sales ...
(Date:9/1/2015)... OAKS, Calif. , Sept. 1, 2015 /PRNewswire/ ... neuroscience collaboration with Novartis in the areas of ... potential entry into Alzheimer,s disease by teaming up ... Alzheimer,s disease program directed at genetically predisposed individuals ... enables Amgen to focus on the commercialization of ...
Breaking Medicine Technology:OncoSec to Present at Scientific and Investment Conferences in September 2OncoSec to Present at Scientific and Investment Conferences in September 3OncoSec to Present at Scientific and Investment Conferences in September 4OncoSec to Present at Scientific and Investment Conferences in September 5China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 10Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 2Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 3Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 4Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 5Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 6Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 7Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 8Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer's Disease And Migraine Programs 9
... IRVINE, California , and ... world leader in molecular cancer diagnostics, today announced the,inauguration ... CA. Previously, Agendia,s offices and laboratory were located ... further increase capacity to,support Agendia,s strong commercial expansion in ...
... Aug. 5 Increased market share is the most ... However, gauging the Return on Investment for pull-through initiatives is a ... a hurdle for increasing pull-through. , ... Difficulty in identifying appropriate metrics ...
Cached Medicine Technology:Agendia Inaugurates New State-of-the-Art Genomics Laboratory in Irvine 2Agendia Inaugurates New State-of-the-Art Genomics Laboratory in Irvine 3Agendia Inaugurates New State-of-the-Art Genomics Laboratory in Irvine 4Managed Care Pull-Through Initiatives Suffer from Poor Measurement of ROI 2
(Date:9/2/2015)... ... ... A recent survey by Consumer Reports ( http://bit.ly/1h67tL8 ) sheds light on the ... It was reported that 33% are paying an average of $39 more out-of-pocket for ... compared to last year. Among the drugs that saw the highest increases were those ...
(Date:9/2/2015)... ... 02, 2015 , ... EDAC Systems, Inc., a leading value-added ... services to both government and commercial clients, today announced the release of a ... Datacap document capture platform. EDAC PurePAGE processes and enhances the images whether ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... PHYTOMER, the pioneer in marine cosmetics introduces PIONNIÈRE XMF Perfection Youth Rich ... new cream combines breakthrough biotechnological anti-aging power with a lipid-replenishing marine oil for ...
(Date:9/2/2015)... ... 02, 2015 , ... Dr. Robert G. Schwartz , the principal of ... “Systema”: a Russian martial art system that is also a philosophy of life that ... which dates back to the 10th century, is a Russian Martial Art that has ...
(Date:9/1/2015)... ... September 01, 2015 , ... An August ... thousands of plastic surgeries conducted each year on teenagers, quoting a New York ... numbers. Beverly Hills-based plastic surgeon Payam Jarrah-Nejad, M.D., F.I.C.S., F.A.C.S., known more familiarly ...
Breaking Medicine News(10 mins):Health News:Watertree Health President Responds to Consumer Reports Survey on Rising Prescription Drug Prices 2Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 2Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 3Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 2Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 3Health News:Phytomer announces PIONNIÈRE XMF Perfection Youth Rich Cream 4Health News:Dr. Robert G. Schwartz Achieves Certification in Russian Martial Art “Systema” and Focuses on Integrating Techniques & Principles into Health Care Delivery 2Health News:Dr. Robert G. Schwartz Achieves Certification in Russian Martial Art “Systema” and Focuses on Integrating Techniques & Principles into Health Care Delivery 3Health News:Teen Plastic Surgery Article Understates the Most Important Realities of Procedures on Young People, Notes Dr. J 2
... recent study at the University of North Carolina in Chapel ... the National Cancer Institute suggests that two genes - C282Y ... hemochromatosis may also lead to an increased risk of developing ... 1,300 subjects were studied, out// of which, more than 400 ...
... A new study by researchers in Charleston has ... depressive disorder in individuals with diabetes. For the ... Health Interview Survey, which was used to evaluate ... researchers found that depressed individuals with diabetes, were ...
... the Johns Hopkins University School of Medicine in Baltimore cautioned ... screening for lung cancer. They claimed that the harm of ... that turn out to be benign,// and the costs of ... annual full-body CT screening. ,Following this, the National Cancer ...
... University in Boston has revealed that children as young as ... They also use emotional information picked up from adults around ... psychology at Tufts University, and her team tested //babies, showing ... red spiral letter holder, a blue bumpy ball, and a ...
... found that continuous combined hormone therapy(estrogen combined with 25 ... associated with an increased breast cancer risk among current ... for five or more years. The study however did ... hormone therapy and breast cancer risk. This indicated that ...
... by removing a disc or placing a bone graft in ... disc which is being studied as a replacement is in ... was recently completed compared the prosthesis to traditional fusion. While ... one having a fusion operation for every two that received ...
Cached Medicine News:Health News:Artificial discs available as replacements for damaged discs 2
... The VersaPulse PowerSuite holmium laser ... properties for precise, virtually bloodless procedures. ... fragmenting urinary and gall bladder stones ... ideal multipurpose surgical tool. Because its ...
... Nd:YAG technology has allowed for perfecting mini-invasive ... of various pathologies with a considerable social ... for reducing the post-operatory times and represents ... costs in all hospital structures.,DEKAs family of ...
... have to choose. The Apogee Elite ... 755nm Alexandrite laser and a high ... in one convenient unit. The ... for hair removal, pigmented lesions, facial ...
Single use trocar with non-conductive sleeves for gaining and maintaining thoracic access., ,THORACOPORT™ devices are trocars used to gain access to the thoracic cavity for use in video assis...
Medicine Products: